Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CHEK Stock Forecast 2026-2027
$1.66
Current Price
$9.71M
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CHEK Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
CHEK Price Momentum
+7.8%
1 Week Change
-5.7%
1 Month Change
+88.6%
1 Year Change
+2.5%
Year-to-Date Change
-57.7%
From 52W High of $3.92
+179.9%
From 52W Low of $0.59
📊 TOP ANALYST CALLS
Did CHEK Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Check Cap is one of their latest high-conviction picks.
Latest CHEK Stock Price Targets & Analyst Predictions
CHEK has shown a year-to-date change of 2.5% and a 1-year change of 88.6%, reflecting upward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for CHEK. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CHEK Analyst Ratings
3
Buy
0
Hold
0
Sell
CHEK Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $1.66
Latest CHEK Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CHEK.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 7, 2023 | HC Wainwright & Co. | Yi Chen | Neutral | Downgrade | $N/A |
| May 15, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $7.00 |
| Apr 5, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $7.00 |
| Aug 9, 2021 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $3.00 |
| Mar 17, 2021 | Dawson James | Neutral | Downgrade | $N/A | |
| Mar 16, 2021 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $4.00 |
| Nov 19, 2020 | HC Wainwright & Co. | Buy | Maintains | $1.50 | |
| Apr 24, 2020 | HC Wainwright & Co. | Buy | Reiterates | $2.00 | |
| Apr 24, 2020 | H.C. Wainwright | Buy | Reiterates | $N/A | |
| Feb 5, 2019 | Dougherty | Buy | Initiates | $N/A | |
| Feb 5, 2019 | Dougherty & Co. | Buy | Initiates | $N/A | |
| May 23, 2018 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $14.00 |
| May 23, 2018 | H.C. Wainwright | Buy | Maintains | $N/A | |
| Mar 16, 2016 | Chardan Capital | Buy | Maintains | $6.00 | |
| Oct 8, 2015 | Maxim Group | Buy | Initiates | $N/A |
Check-Cap Ltd. (CHEK) Competitors
The following stocks are similar to Check Cap based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Check-Cap Ltd. (CHEK) Financial Data
Check-Cap Ltd. has a market capitalization of $9.71M with a P/E ratio of -0.4x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -226.2%.
Valuation Metrics
Market Cap
$9.71M
Enterprise Value
$10.81M
P/E Ratio
-0.4x
PEG Ratio
-0.6x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+2.7%
Current Ratio
0.1x
Debt/Equity
-0.1x
ROE
-226.2%
ROA
-46.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Check-Cap Ltd. (CHEK) Business Model
About Check-Cap Ltd.
What They Do
Develops innovative colorectal cancer screening solutions.
Business Model
The company generates revenue by offering a unique capsule-based screening platform that allows for the detection of polyps and abnormal growths in the colon without the need for bowel preparation. By providing a non-invasive and patient-friendly alternative to traditional screening methods, Check-Cap aims to increase colorectal cancer screening participation rates and improve early detection.
Additional Information
Check-Cap's technology is positioned to significantly enhance patient compliance and outcomes, while potentially lowering healthcare costs related to late-stage diagnoses. The company's focus on preventive care aligns it with healthcare providers and regulators interested in efficient, patient-centered diagnostic solutions, making it a noteworthy player in the healthcare technology sector.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
85
CEO
Mr. David Lontini
Country
Israel
IPO Year
2015
Website
check-cap.comCheck-Cap Ltd. (CHEK) Latest News & Analysis
Latest News
MBody AI ($CHEK) Secures 98% Shareholder Approval to Become Leading Nasdaq Embodied AI Company
2 months ago
Quick Summary
MBody AI ($CHEK) received strong shareholder approval for its merger, enhancing its position as a leader in hardware-agnostic embodied intelligence and enterprise automation.
Why It Matters
MBody AI's merger signals strong shareholder confidence and positions the company as a leader in enterprise automation, likely boosting its market value and attracting further investment.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
MBody AI ($CHEK) is expanding its hardware-agnostic MBody AI Orchestrator platform globally, signaling growth in enterprise deployments as of November 10, 2025.
Why It Matters
MBody AI's global deployment of its platform signals growth and potential revenue increases, indicating strong demand for its technology in the AI sector, which can positively impact stock performance.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
Check-Cap Ltd. offers shareholders exclusive early access to a leading embodied AI company, focusing on global growth and long-term value creation.
Why It Matters
Exclusive early access to a leading AI company signals potential for significant growth and innovation, enhancing long-term value for shareholders, which can positively impact stock performance.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
MediPharm Labs Corp. (TSX: LABS) has filed its Management Information Circular and proxy materials for its Annual and Special Meeting on June 16, 2025, available on SEDAR+.
Why It Matters
MediPharm Labs' upcoming shareholder meeting and proxy materials could impact investor sentiment and decision-making regarding corporate governance and strategic direction.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
MediPharm Labs has not held a shareholder call since Q2 2024 after a significant stock value drop, costing investors $1 billion. Apollo Capital seeks board changes to improve performance.
Why It Matters
Suspension of calls highlights management's avoidance of accountability amid significant stock devaluation. Shareholder activism from Apollo Capital could lead to potential leadership changes and value restoration.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Apollo Technology Capital is urging MediPharm shareholders to vote for board changes, citing a 99% stock price drop and lack of a credible strategic plan. They propose six new director candidates.
Why It Matters
MediPharm's stock plummeting over 99% signals serious governance issues. Shareholder dissatisfaction and proposed board changes may impact future performance and recovery strategies.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About CHEK Stock
What is Check-Cap Ltd.'s (CHEK) stock forecast for 2026?
Analyst forecasts for Check-Cap Ltd. (CHEK) are not currently available. The stock is trading at $1.66.
Is CHEK stock a good investment in 2026?
According to current analyst ratings, CHEK has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.66. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CHEK stock?
Price predictions from Wall Street analysts for CHEK are not currently available. The stock is trading at $1.66.
What is Check-Cap Ltd.'s business model?
The company generates revenue by offering a unique capsule-based screening platform that allows for the detection of polyps and abnormal growths in the colon without the need for bowel preparation. By providing a non-invasive and patient-friendly alternative to traditional screening methods, Check-Cap aims to increase colorectal cancer screening participation rates and improve early detection.
What is the highest forecasted price for CHEK Check-Cap Ltd.?
Price targets from Wall Street analysts for CHEK are not currently available. The stock is trading at $1.66.
What is the lowest forecasted price for CHEK Check-Cap Ltd.?
Price targets from Wall Street analysts for CHEK are not currently available. The stock is trading at $1.66.
What is the overall CHEK consensus from analysts for Check-Cap Ltd.?
The overall analyst consensus for CHEK is bullish. Out of 3 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell.
How accurate are CHEK stock price projections?
Stock price projections, including those for Check-Cap Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: February 10, 2026 2:32 PM UTC